Valeriya V. Vorotyntseva
Valeriya V. Vorotyntseva has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Vadim P. Mikhin
Kursk State Medical University
3 shared publications - Nikolai I. Gromnatskiy2 shared publications
Николай Ильич Громнацкий
Курский государственный медицинский университет (КГМУ)
2 shared publications- D. N. Perutsky
Belgorod State National Research University
1 shared publication - Marina A. Chernyatina
Kursk State Medical University
1 shared publication - N. I. Golovina
Belgorod State National Research University
1 shared publication
Latest Publications
- Open Access
- 3 November 2022
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 21 (10) , 3422
Content of matrix metalloproteinases in the blood of hypertensive patients with a high cardiovascular risk receiving statin therapy
Aim. To compare the effect of atorvastatin and rosuvastatin as part of complex therapy in patients with hypertension (HTN) with a high cardiovascular risk on the level of matrix metalloproteinases -1, -9 (MMP-1, MMP-9) and tissue inhibitors of metalloproteinases -1, -4 (TIMP-1, TIMP-4).Material and methods. The study included 140 hypertensive patients who received atorvastatin (Liprimar) 20 mg/day in addition to antihypertensive therapy for a year, which was later replaced by rosuvastatin (Rosucard) in the following doses: 10 mg/day (n=96), 20 mg/day (n=24), 40 mg/day (n=26). Patients underwent standard clinical and paraclinical investigations. In the blood serum of patients, the levels of MMP-1, MMP-9 and TIMP-1, TIMP-4 were determined.Results. Patients who used rosuvastatin at a dose of 40 mg/day had a more pronounced decrease in MMP-1 than those treated with rosuvastatin at a dose of 10 and 20 mg/day (p0,05). The content of TIMP-1 and TIMP-4 increased when taking rosuvastatin, while a more pronounced dose-dependent increase in TIMP-1 was observed with rosuvastatin 20 mg/day and 40 mg/day. In addition, the largest increase in TIMP-4 was observed when using rosuvastatin at a dose of 40 mg/day. Atorvastatin had no significant effect on MMP-1 and MMP-9, as well as TIMP-1 and TIMP-4.Conclusion. Long-term rosuvastatin therapy (10 mg/day, 20 mg/day, 40 mg/day) as part of the complex therapy of cardiovascular patients affects the metabolism of vascular wall elastin and collagen, reducing the level of MMP-1, MMP-9 and increasing the content of TIMP-1, TIMP-4 in the blood.
- 3 November 2022
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 21 (10) , 3422
Open AccessContent of matrix metalloproteinases in the blood of hypertensive patients with a high cardiovascular risk receiving statin therapy
Aim. To compare the effect of atorvastatin and rosuvastatin as part of complex therapy in patients with hypertension (HTN) with a high cardiovascular risk on the level of matrix metalloproteinases -1, -9 (MMP-1, MMP-9) and tissue inhibitors of metalloproteinases -1, -4 (TIMP-1, TIMP-4).Material and methods. The study included 140 hypertensive patients who received atorvastatin (Liprimar) 20 mg/day in addition to antihypertensive therapy for a year, which was later replaced by rosuvastatin (Rosucard) in the following doses: 10 mg/day (n=96), 20 mg/day (n=24), 40 mg/day (n=26). Patients underwent standard clinical and paraclinical investigations. In the blood serum of patients, the levels of MMP-1, MMP-9 and TIMP-1, TIMP-4 were determined.Results. Patients who used rosuvastatin at a dose of 40 mg/day had a more pronounced decrease in MMP-1 than those treated with rosuvastatin at a dose of 10 and 20 mg/day (p0,05). The content of TIMP-1 and TIMP-4 increased when taking rosuvastatin, while a more pronounced dose-dependent increase in TIMP-1 was observed with rosuvastatin 20 mg/day and 40 mg/day. In addition, the largest increase in TIMP-4 was observed when using rosuvastatin at a dose of 40 mg/day. Atorvastatin had no significant effect on MMP-1 and MMP-9, as well as TIMP-1 and TIMP-4.Conclusion. Long-term rosuvastatin therapy (10 mg/day, 20 mg/day, 40 mg/day) as part of the complex therapy of cardiovascular patients affects the metabolism of vascular wall elastin and collagen, reducing the level of MMP-1, MMP-9 and increasing the content of TIMP-1, TIMP-4 in the blood.
- Open Access
- 1 January 2022
- Published by LLC MedTestInfo in Человек и его здоровье
- Vol. 25 (4) , 28-35
The level of matrix metalloproteinase type 12 in the blood of arterial hypertension patients with high cardiovascular risk on the background of statin therapy
Objective: to evaluate the features of changes in the content of metalloproteinase-12 (MMR-12) in blood serum in patients with arterial hypertension (AH) of high cardiovascular risk (SSR) against the background of therapy with atorvastatin (20 mg/day) or rosuvastatin (10 mg/day; 20 mg/day; 40 mg / day) as part of complex therapy. Materials and methods. The study included 140 patients with stage II hypertension, with partially controlled BP, the duration of the disease is 5-12 years, who, against the background of hypotensive therapy (enalapril 20-40 mg/ day, indapamide retard 1.5 mg, metoprolol 100-150 mg/day) received atorvastatin (Liprimar) 20 mg/day for 1 year, subsequently, it was replaced with rosuvastatin (Rosucard)10, 20, 40 mg / day. The dose regimen was determined by achieving the target level of low-density lipoprotein cholesterol (LDL) and cholesterol (HC). Results. During atorvastatin therapy, the content of MMR-12 in each of the three groups did not change. In the group of patients taking rosuvastatin 10 mg / day, the content of MMP-12 did not change for 18 months In the group of patients taking rosuvastine 20 mg / day, a decrease in MMP-12 was observed only by 12 months of therapy - by 26.8%, by 18 months - by 30.4% (p<0.05) When taking rosuvastine 40 mg / day, a decrease in MMP-12 was observed by 24.1% by 6 months, by 12 months - by 35.3%, by 18 months - by 37.1% (p<0.05). Conclusion. In patients with hypertension with high SSR, rosuvastatin as part of a complex therapy had an ambiguous effect on the content of MMR-12 in the blood, the greatest decrease in the level of MMR-12 was registered when taking 40 mg / day of rosuvastatin.
- 1 January 2022
- Published by LLC MedTestInfo in Человек и его здоровье
- Vol. 25 (4) , 28-35
Open AccessThe level of matrix metalloproteinase type 12 in the blood of arterial hypertension patients with high cardiovascular risk on the background of statin therapy
Objective: to evaluate the features of changes in the content of metalloproteinase-12 (MMR-12) in blood serum in patients with arterial hypertension (AH) of high cardiovascular risk (SSR) against the background of therapy with atorvastatin (20 mg/day) or rosuvastatin (10 mg/day; 20 mg/day; 40 mg / day) as part of complex therapy. Materials and methods. The study included 140 patients with stage II hypertension, with partially controlled BP, the duration of the disease is 5-12 years, who, against the background of hypotensive therapy (enalapril 20-40 mg/ day, indapamide retard 1.5 mg, metoprolol 100-150 mg/day) received atorvastatin (Liprimar) 20 mg/day for 1 year, subsequently, it was replaced with rosuvastatin (Rosucard)10, 20, 40 mg / day. The dose regimen was determined by achieving the target level of low-density lipoprotein cholesterol (LDL) and cholesterol (HC). Results. During atorvastatin therapy, the content of MMR-12 in each of the three groups did not change. In the group of patients taking rosuvastatin 10 mg / day, the content of MMP-12 did not change for 18 months In the group of patients taking rosuvastine 20 mg / day, a decrease in MMP-12 was observed only by 12 months of therapy - by 26.8%, by 18 months - by 30.4% (p<0.05) When taking rosuvastine 40 mg / day, a decrease in MMP-12 was observed by 24.1% by 6 months, by 12 months - by 35.3%, by 18 months - by 37.1% (p<0.05). Conclusion. In patients with hypertension with high SSR, rosuvastatin as part of a complex therapy had an ambiguous effect on the content of MMR-12 in the blood, the greatest decrease in the level of MMR-12 was registered when taking 40 mg / day of rosuvastatin.
- Open Access
- 1 December 2020
- Published by LLC MedTestInfo in Человек и его здоровье
- No. 4,p. 37-45
Changes in the elasticity of the vascular wall of arteries and markers of angiopathy on the background of long statin therapy in patients with arterial hypertension with high cardiovascular risk
Objective. To determine the comparative effectiveness of atorvastatin and rosuvastatin in relation to individual biochemical and functional markers of vascular wall remodeling in patients with arterial hypertension of high cardiovascular risk. Materials and methods. The study included 140 patients with stage II of arterial hypertension (AH), II-III degree of severity with the duration of the disease from 5 to 12 years, who, against the background of antihypertensive therapy (enalapril 20-40 mg/day, indapamide retard 1.5 mg, metoprolol 100-150 mg/days) received atorvastatin 20 mg/day for 1 year, subsequently it was replaced by rosuvastatin 10, 20, 40 mg / day. The dose regimen was determined by achieving the target level of cholesterol (CS) and low density lipoprotein cholesterol (LDL-C). Results. Taking atorvastatin for 1 year was accompanied by a decrease in the value of the cardio-ankle vascular index (CAVI) by 14.4%, the augmentation index (AI) - by 10.3%. The replacement of atorvastatin with rosuvastatin was accompanied by a further decrease in the R-CAVI value: by 10.8% (20 mg/day) and 14.4% (40 mg/day). The use of atorvastatin for 1 year was accompanied by a decrease in both C-reactive protein (CRP) (by 26.0%) and osteopontin (OP) (by 22.8%). A further decrease in the concentration of CRP by 18 months of rosuvastatin therapy is recorded when using mean and high doses (20-40 mg/day). Differences in the severity of changes in CRP level between the groups were significant (p<0.05). The level of OP in comparison with the beginning of rosuvastatin decreased by 32.9%. Differences in the degree of reduction of OP when taking rosuvastatin between the groups were significant (P<0.05). Conclusion. Rosuvastatin in various dosage regimens with long-term use in patients with arterial hypertension with a high vascular risk reduces the content of CRP and OP in blood, reduces the CAVI and the AI, and is more effective than 20 mg atorvastatin a day.
- 1 December 2020
- Published by LLC MedTestInfo in Человек и его здоровье
- No. 4,p. 37-45
Open AccessChanges in the elasticity of the vascular wall of arteries and markers of angiopathy on the background of long statin therapy in patients with arterial hypertension with high cardiovascular risk
Objective. To determine the comparative effectiveness of atorvastatin and rosuvastatin in relation to individual biochemical and functional markers of vascular wall remodeling in patients with arterial hypertension of high cardiovascular risk. Materials and methods. The study included 140 patients with stage II of arterial hypertension (AH), II-III degree of severity with the duration of the disease from 5 to 12 years, who, against the background of antihypertensive therapy (enalapril 20-40 mg/day, indapamide retard 1.5 mg, metoprolol 100-150 mg/days) received atorvastatin 20 mg/day for 1 year, subsequently it was replaced by rosuvastatin 10, 20, 40 mg / day. The dose regimen was determined by achieving the target level of cholesterol (CS) and low density lipoprotein cholesterol (LDL-C). Results. Taking atorvastatin for 1 year was accompanied by a decrease in the value of the cardio-ankle vascular index (CAVI) by 14.4%, the augmentation index (AI) - by 10.3%. The replacement of atorvastatin with rosuvastatin was accompanied by a further decrease in the R-CAVI value: by 10.8% (20 mg/day) and 14.4% (40 mg/day). The use of atorvastatin for 1 year was accompanied by a decrease in both C-reactive protein (CRP) (by 26.0%) and osteopontin (OP) (by 22.8%). A further decrease in the concentration of CRP by 18 months of rosuvastatin therapy is recorded when using mean and high doses (20-40 mg/day). Differences in the severity of changes in CRP level between the groups were significant (p<0.05). The level of OP in comparison with the beginning of rosuvastatin decreased by 32.9%. Differences in the degree of reduction of OP when taking rosuvastatin between the groups were significant (P<0.05). Conclusion. Rosuvastatin in various dosage regimens with long-term use in patients with arterial hypertension with a high vascular risk reduces the content of CRP and OP in blood, reduces the CAVI and the AI, and is more effective than 20 mg atorvastatin a day.